Your browser doesn't support javascript.
loading
Examining the Use of Real-World Evidence in the Regulatory Process.
Beaulieu-Jones, Brett K; Finlayson, Samuel G; Yuan, William; Altman, Russ B; Kohane, Isaac S; Prasad, Vinay; Yu, Kun-Hsing.
Afiliação
  • Beaulieu-Jones BK; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
  • Finlayson SG; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
  • Yuan W; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
  • Altman RB; Departments of Bioengineering, Genetics, Medicine, and Biomedical Data Science, Stanford University, Stanford, California, USA.
  • Kohane IS; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
  • Prasad V; Division of Hematology Oncology, Department of Public Health and Preventive Medicine, Center for Health Care Ethics, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Yu KH; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
Clin Pharmacol Ther ; 107(4): 843-852, 2020 04.
Article em En | MEDLINE | ID: mdl-31562770
The 21st Century Cures Act passed by the United States Congress mandates the US Food and Drug Administration to develop guidance to evaluate the use of real-world evidence (RWE) to support the regulatory process. RWE has generated important medical discoveries, especially in areas where traditional clinical trials would be unethical or infeasible. However, RWE suffers from several issues that hinder its ability to provide proof of treatment efficacy at a level comparable to randomized controlled trials. In this review article, we summarized the advantages and limitations of RWE, identified the key opportunities for RWE, and pointed the way forward to maximize the potential of RWE for regulatory purposes.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: United States Food and Drug Administration / Ensaios Clínicos como Assunto / Medicina Baseada em Evidências Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Clin Pharmacol Ther Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: United States Food and Drug Administration / Ensaios Clínicos como Assunto / Medicina Baseada em Evidências Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Clin Pharmacol Ther Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos